Table 1 Patient characteristics, adjusted

Age, median (range), years

69 (48–82)

68 (52–79)

0.204

PSA at diagnosis, median (range), ng/mL

7.9 (2.6–18.5)

7.3 (2.9–19.8)

0.697

Clinical stage, number (%)

0.562

 T1c

101 (47.1%)

107 (50.0%)

 T2a–c

113 (52.9%)

107 (50.0%)

Gleason grade, number (%)

0.770

 1

41 (19.2%)

36 (16.8%)

 2

112 (52.3%)

112 (52.3%)

 3

61 (28.5%)

66 (30.9%)

Positive biopsy core rate, number (%)

0.552

  < 34%

128 (59.8%)

134 (62.6%)

  ≥ 34%

86 (40.2%)

80 (37.4%)

Favorable intermediate-risk, number (%)

101 (47.2%)

100 (46.7%)

0.923

Follow-up, median (range), mos

96 (1–153)

94 (11–158)

0.499

Neoadjuvant hormonal therapy yes, number (%)

65 (30.3%)

9 (4.2%)

–

Adjuvant hormonal therapy yes, number (%)

0 (0.0%)

0 (0.0%)

–

Salvage radiotherapy, number (%)

–

43 (20.0%)

–

Positive surgical margin, number (%)

–

63 (29.4%)

–

 Open surgery (n = 121), number (%)

42 (34.7%)

 Laparoscopic surgery (n = 93), number (%)

21 (22.5%)

Combined EBRT, number (%)

53 (24.7%)

–

–

 Favorable intermediate-risk

12 (5.60%)

 Unfavorable intermediate-risk

41 (19.1%)

Prostate D90 at 1 month, Gy

 SEED-BT alone

185.6 (141.0–255.0)

–

 Combined EBRT

124.4 (99.4–180.8)

–

Prostate V100 at 1 month, Gy

 SEED-BT alone

97.9% (80.1–100)

–

 Combined EBRT

96.9% (90.0–99.3)

–

Prostate V150 at 1 month, Gy

 SEED-BT alone

69.2% (23.4–97.3)

–

 Combined EBRT

62.4% (42.6–84.8)

–

BED, Gy2

218.0 (147.9–284.1)

–